Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Titel:
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Auteur:
Mezynski, J. Pezaro, C. Bianchini, D. Zivi, A. Sandhu, S. Thompson, E. Hunt, J. Sheridan, E. Baikady, B. Sarvadikar, A. Maier, G. Reid, A.H.M. Mulick Cassidy, A. Olmos, D. Attard, G. de Bono, J.